Literature DB >> 10423157

Host and transmissible spongiform encephalopathy agent strain control glycosylation of PrP.

R A Somerville.   

Abstract

PrP is a host-encoded glycoprotein involved in the pathogenesis of transmissible spongiform encephalopathies (TSEs) or 'prion' diseases. The normal form of the protein (PrP(C)) is heavily but incompletely glycosylated; it shows structural diversity in three neuroanatomically distinct regions of the brain. No effect of TSE infection on PrP(C) glycosylation has been detected. TSE-specific forms of PrP (PrP(Sc)) vary in their degree of glycosylation according to strain of TSE infectious agent. PrP(Sc) also varies independently in the amount and pattern of glycosylation according to brain region. This diversity shows that the glycosylation of PrP is under both host- and TSE agent-specified control, probably within the biosynthetic pathway for protein N-glycosylation. These findings challenge assumptions that PrP(Sc) is formed from the normal, mature form of PrP(Sc) but are compatible with a model in which the glycosylation phenotype of PrP(Sc) is under the control of both host cellular factors and TSE agent-specified information.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423157     DOI: 10.1099/0022-1317-80-7-1865

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Distance of sequons to the C-terminus influences the cellular N-glycosylation of the prion protein.

Authors:  Adrian R Walmsley; Nigel M Hooper
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

2.  Molecular analysis of cases of Italian sheep scrapie and comparison with cases of bovine spongiform encephalopathy (BSE) and experimental BSE in sheep.

Authors:  Romolo Nonno; Elena Esposito; Gabriele Vaccari; Michela Conte; Stefano Marcon; Michele Di Bari; Ciriaco Ligios; Giovanni Di Guardo; Umberto Agrimi
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 3.  N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.

Authors:  Lucia F Zacchi; Benjamin L Schulz
Journal:  Glycoconj J       Date:  2015-12-05       Impact factor: 2.916

4.  Proteolytic processing and glycosylation influence formation of porcine prion protein complexes.

Authors:  Krzysztof Nieznanski; Marcin Rutkowski; Magdalena Dominik; Dariusz Stepkowski
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

5.  Molecular profiling of ovine prion diseases by using thermolysin-resistant PrPSc and endogenous C2 PrP fragments.

Authors:  Jonathan P Owen; Helen C Rees; Ben C Maddison; Linda A Terry; Leigh Thorne; Roy Jackman; Garry C Whitelam; Kevin C Gough
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

6.  Comparison of abnormal prion protein glycoform patterns from transmissible spongiform encephalopathy agent-infected deer, elk, sheep, and cattle.

Authors:  Richard E Race; Anne Raines; Thierry G M Baron; Michael W Miller; Allen Jenny; Elizabeth S Williams
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Posttranslational modifications define course of prion strain adaptation and disease phenotype.

Authors:  Natallia Makarava; Jennifer Chen-Yu Chang; Kara Molesworth; Ilia V Baskakov
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

8.  Molecular polymorphism of Abeta in Alzheimer's disease.

Authors:  Harry Levine; Lary C Walker
Journal:  Neurobiol Aging       Date:  2008-07-10       Impact factor: 4.673

9.  Glycan-controlled epitopes of prion protein include a major determinant of susceptibility to sheep scrapie.

Authors:  Mohammed Moudjou; Eric Treguer; Human Rezaei; Elifsu Sabuncu; Erdmute Neuendorf; Martin H Groschup; Jeanne Grosclaude; Hubert Laude; Erdi Neuendorf
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Species and strain glycosylation patterns of PrPSc.

Authors:  Konstantinos Xanthopoulos; Magdalini Polymenidou; Sue J Bellworthy; Sylvie L Benestad; Theodoros Sklaviadis
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.